Wockhardt Recalls Famotodine Tablets Due to CGMP Deviations
Wockhardt USA Inc. is recalling Famotodine Tablets, USP, 40 mg due to inadequate investigation of customer complaints.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a CGMP deviation regarding complaint investigation without reported injuries or illnesses, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Wockhardt USA Inc. is recalling Famotodine Tablets, USP, 40 mg, which are packaged in 30, 100, and 1000 count bottles. The product is prescription-only and was distributed nationwide in the United States, including Puerto Rico.
The recall was initiated because the firm did not adequately investigate customer complaints, which constitutes a Current Good Manufacturing Practice (CGMP) deviation. The FDA has classified this recall as Class II.
Consumers with this medication should contact their healthcare provider or pharmacist for guidance on how to proceed.
The recalled product
- Product
- Famotodine Tablets, USP, 40 mg Tablets, Packaged in A) 30 Count Bottles (NDC: 64679-937-01), B) 100 Count Bottles (NDC: 64679-937-02), and C) 1000 Count Bottles (NDC: 64679-937-03), Rx only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC…
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- A) Lot #: LM10806
- Expiry: 5/31/2015
- Lot #: LM11099
- Expiry: 6/30/2015
- Lot #: LM11297
- Expiry: 7/31/2015
- Lot #: LM11933
- Expiry: 10/31/2015
- Lot #: LN10180
- Expiry: 12/31/2015
- Lot #: LN10547
- Expiry: 2/29/2016. B) Lot #: LM10784
- Lot #: LM10791
- Lot #: LM10812
- Lot #: LM11112
- Lot #: LM11298
- Lot #: LM11299
- Lot #: LM11625
- Expiry: 8/31/2015
- Lot #: LN10182
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- ModerateFamotidine tablets recalled for inadequate complaint investigation
FDA (Drugs) · 2015-07-15
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Captopril Tablets for Thickness Specification Failures
FDA (Drugs) · 2015-05-13
- ModerateAmlodipine besylate tablets recalled for inadequate complaint investigation
FDA (Drugs) · 2015-07-15
- ModerateWockhardt Recalls Pantaprazole Sodium Tablets Due to Dissolution Failure
FDA (Drugs) · 2014-02-05
- ModerateAmerican Health Packaging Recalls Lisinopril Tablets Due to CGMP Deviations
FDA (Drugs) · 2015-07-15